• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Differential protease expression by cutaneous squamous and basal cell carcinomas.

作者信息

Sappino A P, Belin D, Huarte J, Hirschel-Scholz S, Saurat J H, Vassalli J D

机构信息

Division of Onco-Haematology, University of Geneva Medical School, Switzerland.

出版信息

J Clin Invest. 1991 Oct;88(4):1073-9. doi: 10.1172/JCI115406.

DOI:10.1172/JCI115406
PMID:1918364
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC295554/
Abstract

To assess the postulated role of plasminogen activation in tumor invasion, we have investigated the cellular sites of synthesis for urokinase-type (uPA) and tissue-type (tPA) plasminogen activators and their inhibitors (PAI-1 and PAI-2) in two human cutaneous neoplasia that differ in their metastatic potential. The combined use of zymography on tissue sections and in situ hybridization demonstrates that uPA is produced by malignant cells of squamous cell carcinomas (SCC) but not by basal cell carcinomas (BCC), whereas tPA is detected exclusively in nonmalignant dermal tissue. In addition, we show that SCC neoplastic cells simultaneously produce variable amounts of PAI-1, and that PAI-1 production correlates inversely with uPA enzymatic activity. These observations establish that invasive human malignant cells in vivo can activate plasminogen through uPA production during the early phases of tumor growth; they also demonstrate that the proteolytic activity of tumor cells can be modulated by the concomitant production of PAI-1. Because SCC have a higher invasive and metastatic potential than BCC, our findings lend further support to the involvement of plasminogen activation in malignant behavior.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/67b70de3702a/jcinvest00063-0028-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/dbed845b87b7/jcinvest00063-0024-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/eb2c8930ec9a/jcinvest00063-0024-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/dab5ae95ff04/jcinvest00063-0024-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/96d3952a12bf/jcinvest00063-0024-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/53f9ed8e67eb/jcinvest00063-0024-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/e754550c4e61/jcinvest00063-0024-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/50288f150028/jcinvest00063-0025-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/b049e5bc857c/jcinvest00063-0025-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/5a2d8aec3ecb/jcinvest00063-0025-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/8d5ba5ccd047/jcinvest00063-0025-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/a7a43f6213f7/jcinvest00063-0025-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/c6de40d2f112/jcinvest00063-0025-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/b909c7746d1c/jcinvest00063-0025-g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/5da574483ee5/jcinvest00063-0026-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/7555299ce355/jcinvest00063-0027-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/f9f42ec0e0ba/jcinvest00063-0027-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/a5e13b36e317/jcinvest00063-0027-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/393bebc563a9/jcinvest00063-0027-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/190bc9a7fb28/jcinvest00063-0027-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/a6d952b017a0/jcinvest00063-0028-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/258e7f9fa14e/jcinvest00063-0028-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/8121c696efea/jcinvest00063-0028-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/b75a867b6935/jcinvest00063-0028-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/97e85d64bb91/jcinvest00063-0028-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/67b70de3702a/jcinvest00063-0028-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/dbed845b87b7/jcinvest00063-0024-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/eb2c8930ec9a/jcinvest00063-0024-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/dab5ae95ff04/jcinvest00063-0024-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/96d3952a12bf/jcinvest00063-0024-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/53f9ed8e67eb/jcinvest00063-0024-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/e754550c4e61/jcinvest00063-0024-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/50288f150028/jcinvest00063-0025-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/b049e5bc857c/jcinvest00063-0025-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/5a2d8aec3ecb/jcinvest00063-0025-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/8d5ba5ccd047/jcinvest00063-0025-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/a7a43f6213f7/jcinvest00063-0025-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/c6de40d2f112/jcinvest00063-0025-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/b909c7746d1c/jcinvest00063-0025-g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/5da574483ee5/jcinvest00063-0026-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/7555299ce355/jcinvest00063-0027-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/f9f42ec0e0ba/jcinvest00063-0027-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/a5e13b36e317/jcinvest00063-0027-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/393bebc563a9/jcinvest00063-0027-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/190bc9a7fb28/jcinvest00063-0027-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/a6d952b017a0/jcinvest00063-0028-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/258e7f9fa14e/jcinvest00063-0028-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/8121c696efea/jcinvest00063-0028-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/b75a867b6935/jcinvest00063-0028-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/97e85d64bb91/jcinvest00063-0028-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1223/295554/67b70de3702a/jcinvest00063-0028-f.jpg

相似文献

1
Differential protease expression by cutaneous squamous and basal cell carcinomas.
J Clin Invest. 1991 Oct;88(4):1073-9. doi: 10.1172/JCI115406.
2
Plasminogen activator system in oral squamous cell carcinoma.口腔鳞状细胞癌中的纤溶酶原激活物系统
Br J Oral Maxillofac Surg. 2007 Dec;45(8):623-7. doi: 10.1016/j.bjoms.2007.04.021. Epub 2007 Jun 21.
3
[Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].[尿激酶型纤溶酶原激活剂及其抑制剂在人喉鳞状细胞癌中的表达及意义]
Zhonghua Er Bi Yan Hou Ke Za Zhi. 2003 Feb;38(1):39-42.
4
The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.乳腺肿瘤组织基质中的尿激酶系统与乳腺癌细胞侵袭
Int J Oncol. 2009 Jan;34(1):15-23.
5
Plasminogen activators and their inhibitor gene expression in cutaneous NF1-related neurofibromas.
Arch Dermatol Res. 2006 Mar;297(9):421-4. doi: 10.1007/s00403-005-0637-x. Epub 2006 Jan 12.
6
Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.前列腺素E2调节大鼠颅骨成骨细胞原代培养物中纤溶酶原激活物同工酶、尿激酶受体和纤溶酶原激活物抑制剂-1的产生。
J Cell Physiol. 1995 Dec;165(3):521-9. doi: 10.1002/jcp.1041650310.
7
Expression and release of plasminogen activators, their inhibitors and receptor by human tumor cell lines.人肿瘤细胞系中纤溶酶原激活剂、其抑制剂及受体的表达与释放
Anticancer Res. 1994 Nov-Dec;14(6B):2445-51.
8
Elimination of hydrocortisone from the medium enables tissue plasminogen activator gene expression by normal and immortalized nonmalignant human epithelial cells.从培养基中去除氢化可的松可使正常和永生化的非恶性人上皮细胞表达组织纤溶酶原激活物基因。
Biol Chem. 2001 Nov;382(11):1563-73. doi: 10.1515/BC.2001.191.
9
Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.人鳞状癌细胞系通过纤溶酶原激活剂介导的内皮下细胞外基质降解
Cancer Commun. 1990;2(5):189-99.
10
Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.尿激酶型纤溶酶原激活物、纤溶酶原激活物受体及纤溶酶原激活物抑制剂-2在正常人体子宫内膜和子宫内膜癌中的mRNA差异表达
Gynecol Oncol. 2000 Nov;79(2):244-50. doi: 10.1006/gyno.2000.5959.

引用本文的文献

1
Plasminogen Activator Inhibitor-1 in Skin Malignancies: Therapeutic Implications of Its Inhibition.皮肤恶性肿瘤中的纤溶酶原激活物抑制剂-1:抑制它的治疗意义
Biomolecules. 2025 Sep 13;15(9):1317. doi: 10.3390/biom15091317.
2
PAI-1 in Skin Malignancies: a Central Regulator of Tumor Progression and Therapeutic Resistance.
Curr Treat Options Oncol. 2025 Sep 26. doi: 10.1007/s11864-025-01357-x.
3
Urokinase-controlled tumor penetrating peptide.尿激酶控制的肿瘤穿透肽。
J Control Release. 2016 Jun 28;232:188-95. doi: 10.1016/j.jconrel.2016.04.027. Epub 2016 Apr 19.

本文引用的文献

1
Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA.未剪接的人尿激酶聚腺苷酸加尾RNA的鉴定及一级序列
Proc Natl Acad Sci U S A. 1984 Aug;81(15):4727-31. doi: 10.1073/pnas.81.15.4727.
2
Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex.
Proc Natl Acad Sci U S A. 1983 Nov;80(22):6804-8. doi: 10.1073/pnas.80.22.6804.
3
Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells.牛内皮细胞产生的一种异常稳定的纤溶抑制剂的检测。
4
Transforming growth factor-Beta and urokinase-type plasminogen activator: dangerous partners in tumorigenesis-implications in skin cancer.转化生长因子-β与尿激酶型纤溶酶原激活剂:肿瘤发生中的危险组合——对皮肤癌的影响
ISRN Dermatol. 2013 Jul 18;2013:597927. doi: 10.1155/2013/597927. eCollection 2013.
5
The MMP activity in developing rat molar roots and incisors demonstrated by in situ zymography.通过原位酶谱法显示发育中大鼠磨牙牙根和切牙中的基质金属蛋白酶活性。
J Mol Histol. 2006 Jan;37(1-2):87-93. doi: 10.1007/s10735-006-9037-6. Epub 2006 Jul 8.
6
Epidermal expression of serine protease, neuropsin (KLK8) in normal and pathological skin samples.丝氨酸蛋白酶神经蛋白酶(KLK8)在正常和病理皮肤样本中的表皮表达。
Mol Pathol. 2002 Aug;55(4):235-41. doi: 10.1136/mp.55.4.235.
7
Urokinase-type plasminogen activator and its receptor synergize to promote pathogenic proteolysis.尿激酶型纤溶酶原激活剂及其受体协同促进致病性蛋白水解。
EMBO J. 2000 Sep 1;19(17):4817-26. doi: 10.1093/emboj/19.17.4817.
8
Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.尿激酶型纤溶酶原激活物及其受体和纤溶酶原激活物抑制剂-2在食管鳞状细胞癌中的细胞分布及临床价值
Am J Pathol. 2000 Feb;156(2):567-75. doi: 10.1016/S0002-9440(10)64761-X.
9
Alterations in plasminogen activation correlate with epithelial cell dysplasia grading in colorectal adenomas.纤溶酶原激活的改变与结直肠腺瘤中上皮细胞发育异常分级相关。
Br J Cancer. 1998;77(2):297-304. doi: 10.1038/bjc.1998.46.
10
Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.滑膜组织中的纤溶酶原激活:正常关节、骨关节炎关节和类风湿关节炎关节之间的差异
Ann Rheum Dis. 1997 Sep;56(9):550-7. doi: 10.1136/ard.56.9.550.
Proc Natl Acad Sci U S A. 1983 May;80(10):2956-60. doi: 10.1073/pnas.80.10.2956.
4
Antibodies to plasminogen activator inhibit human tumor metastasis.纤溶酶原激活物抗体可抑制人类肿瘤转移。
Cell. 1983 Dec;35(3 Pt 2):611-9. doi: 10.1016/0092-8674(83)90093-4.
5
Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells.蛋白酶连接蛋白:一种细胞成分,它连接凝血酶和纤溶酶原激活剂,并介导它们与细胞的结合。
Cell. 1980 Aug;21(1):37-45. doi: 10.1016/0092-8674(80)90112-9.
6
Increase in urokinase plasminogen activator mRNA synthesis in human carcinoma cells is a primary effect of the potent tumor promoter, phorbol myristate acetate.强效肿瘤启动子佛波醇肉豆蔻酸酯乙酸盐的主要作用是使人癌细胞中尿激酶型纤溶酶原激活物信使核糖核酸的合成增加。
J Cell Biol. 1986 Apr;102(4):1235-41. doi: 10.1083/jcb.102.4.1235.
7
A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase.人纤溶酶原激活剂尿激酶55,000道尔顿形式的细胞结合位点。
J Cell Biol. 1985 Jan;100(1):86-92. doi: 10.1083/jcb.100.1.86.
8
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines.在20种人类肿瘤细胞系中分析了纤溶酶原激活剂、纤溶酶原激活剂抑制剂和促凝剂。
Int J Cancer. 1986 Nov 15;38(5):719-27. doi: 10.1002/ijc.2910380516.
9
Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma.从妊娠血浆中分离出一种新的特异性纤溶酶原激活物抑制剂。
Br J Haematol. 1986 Feb;62(2):221-8. doi: 10.1111/j.1365-2141.1986.tb02925.x.
10
Detection of transforming growth factor alpha in normal, malignant, and hyperproliferative human keratinocytes.在正常、恶性和过度增殖的人角质形成细胞中检测转化生长因子α
J Exp Med. 1988 Feb 1;167(2):670-5. doi: 10.1084/jem.167.2.670.